Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05254574

Sustained Acoustic Medicine for Osteoarthritis Pain

The purpose of this study is to compare Sustained Acoustic Medicine treatment to topical pain relief gel for the symptomatic management of osteoarthritis. The study will measure pain and function scores for patients undergoing treatment.

Recruiting

Interested in participating?

Request Info

Key information

Age range

35 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

James A Haley Veterans Hospital

Tampa, Florida, 33511, United States

Location status: Recruiting

Location contact

Samuel Phillips, Ph.D.

CONTACT

[email protected]

813-558-3945

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Have physician-diagnosed mild to moderate knee, shoulder, elbow, ankle, hip, or spine osteoarthritis OA (OARSI atlas grades 1-2) or also referred to as Degenerative Joint Disease (DJD).
  • Fulfill the American College of Rheumatology clinical and radiological diagnostic criteria for knee OA
  • Are between 35-85 years of age
  • Report a frequent pain score between 3-7 (range: 0-10) during the week preceding enrollment
  • Report that knee, shoulder, elbow, ankle, hip, or spine pain negatively affects quality of life
  • Are willing not to use any cream, gel, or topical solution during the administration of treatment other than the approved treatment provided to the subject at the initiation of the study
  • Are deemed appropriate by their physician or by the study site physician to participate.
  • Be willing and able to self-administer treatment daily within their place of residence or during normal daily activity, excluding bathing, showering, or other water activities which may result in submersion of the study device.
  • Not use or initiate opioid and/or non-opioid analgesic medications.
  • Be willing to discontinue any other interventional treatment modalities on the treatment area during the study period (e.g., transcutaneous electrical nerve stimulation, electronic muscle stimulation, traditional ultrasound).

Exclusion criteria

  • Cannot successfully demonstrate the ability to put on and take off the device.
  • Displays any condition which, in the judgment of the investigator, would make participation in the study unacceptable including, but not limited to, the subject's ability to understand and follow instructions.
  • Participated in a clinical trial for an investigational drug and/or agent within 30 days prior to screening.
  • Is pregnant.
  • Is a prisoner.
  • Has a pacemaker.
  • Has a malignancy in the treatment area.
  • Has an active infection, open sores, or wounds in the treatment area.
  • Has impaired sensation in the treatment area, such as caused by chemotherapy or anesthesia.
  • Has a known neuropathy (disease of the brain or spinal nerves).
  • Has a hereditary disposition (tendency) for excessive bleeding (hemorrhage).
  • Have knee, shoulder, elbow, ankle, or hip replacement or other surgical intervention, in the affected area in the past 6 months.
  • Requires oxygen support
  • Has an allergy to aspirin or other NSAIDs
  • Have a secondary cause of arthritis (metabolic or inflammatory)

Treatment and study plan

Sustained Acoustic Device with 2.5% Diclofenac Patch

Device

Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3 megahertz(MHz) frequency and 0.132 Watts/cm@ with 2.5% Diclofenac patches.

Other names: ZetrOZ Ultrasound Device, Wearable Ultrasound Device, Long Duration Ultrasound, LITUS DeviceWearable, Long Duration Low-Intensity Device

2.5% Diclofenac Patches

Drug

Topical pain relief-gel worn for 4 hours at least 5 days a week via SAM patch.

Primary outcomes

  1. Change in Pain Units on a Scale (0-10) 0 Being Least, 10 Being Worst Pain From Baseline

    Time frame: Through study completion, average of 8 weeks

    Change in the self described pain units on a scale by patient at baseline and post-

  2. Change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)

    Time frame: Time Frame: Through study completion, average of 8 weeks

    WOMAC questionnaire will be utilized (Western Ontario and McMaster Universities Arthritis Index) at baseline and post-treatment to calculate the change in scores. WOMAC was divided into 3 categories: pain, stiffness, function and total score. The pain category consists of five scores from 0 - 4, 0 being no pain 4 is worst pain possible, for a range of 0 - 20 points. The stiffness category consists of two scores from 0 - 4, 0 being no stiffness 10 is worst stiffness possible for a range of 0 - 8 points. The function score consists of 17 scores from 0 - 4, 0 being normal function and 10 is severely limited function, for a range of 0 - 68 points. Total score is the sum of pain, stiffness, and function scores (range of 0 - 96).

Secondary outcomes

  1. Change in Global Rating of Change (GROC) on a Scale (-7 to +7)

    Time frame: Through study completion, average of 24 weeks.

    Subject-reported change in overall pain on a scale, -7 = worst, +7 = best.

  2. Change in the Pain & Sleep Questionnaire (PSQ-3)

    Time frame: Through study completion, average of 24 weeks.

    Subject-reported rating of impact of pain on sleep on a scale from 0 no impact, to 100 greatest impact

  3. Change in Depression Anxiety Stress Scale (DASS21)

    Time frame: Through study completion, average of 24 weeks.

    Subject-reported measures of depression, anxiety, and stress on a scale of 0-3, 0 being not applicable, 1 meaning applicable to some degree, 2 meaning applicable often, and 3 meaning applicable most of the time. Questions are divided into three categories: depression, anxiety, and stress.

Study contacts

Contact information is provided by the study sponsor or research team.

George K. Lewis, Ph.D.

CONTACT

[email protected]

888-202-9831

Sponsors and collaborators

Lead sponsor

ZetrOZ, Inc.

Industry

Registry information

Important dates

Study start
2022
Primary completion
2026
Study completion
2026
First posted
Feb 24, 2022
Registry last updated
Feb 27, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.